Intellia Therapeutics is advancing NTLA-2001, a CRISPR/Cas9-based therapeutic targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This Phase 3 trial, MAGNITUDE, aims to establish NTLA-2001's efficacy and safety compared to placebo in approximately 1,200 participants. The ATTR-CM market is growing, driven by increasing diagnosis rates and the need for effective therapies. Competitive landscape includes existing treatments like tafamidis and patisiran, but NTLA-2001's novel mechanism may provide a significant advantage if proven effective. Successful trial outcomes could position Intellia as a leader in the ATTR-CM space, enhancing its market valuation and attracting potential partnerships or acquisitions.